Fig. 3

SBP-specific immunoglobulin titers for all mice in three independent experiments. a SBP-specific IgE titer of FPP-fed (F, n = 16), 10-fold-diluted FPP-fed (D, n = 16) and saline-fed (S, n = 30) mice at pre- (day 35) and post- (day 41) intranasal challenge with SBP. SBP-specific IgE titer for pooled sera from SBP-sensitized mice was used as standard serum and was determined as 1 kAU/L. Statistical significance was determined by nonrepeated ANOVA. b SBP-specific IgG titer of FPP-fed (F, n = 16), 10-fold-diluted FPP-fed (D, n = 16) and saline-fed (S, n = 30) mice at pre- (day 35) and post- (day 41) intranasal challenge with SBP. SBP-specific IgG titer for pooled sera from SBP-sensitized mice was used as standard serum and was determined as 1 kAU/L. Statistical significance was determined by nonrepeated ANOVA. c Intensity of SBP-specific IgA of FPP-fed (F, n = 16), 10-fold-diluted FPP-fed (D, n = 16) and saline-fed (S, n = 30) mice at pre- (day 35) and post- (day 41) intranasal challenge with SBP. Absorbance for 450 nm was plotted on the y-axis for each mouse after a colorimetric ELISA for SBP-specific IgA. The significance of differences was determined by nonrepeated ANOVA. d The inhibition of binding between SBP and serum IgE by serum immunoglobulins of FPP-fed (F, n = 16), 10-fold-diluted FPP-fed (D, n = 16) and saline-fed (S, n = 30) mice at pre- (day 35) and post- (day 41) intranasal challenge with SBP is shown as the inhibition rate. The significance of differences was determined by nonrepeated ANOVA